Design Therapeutics Inc
$ 9.10
-2.99%
02 Jan - close price
- Market Cap 534,320,000 USD
- Current Price $ 9.10
- High / Low $ 9.71 / 8.94
- Stock P/E N/A
- Book Value 3.51
- EPS -1.19
- Next Earning Report 2026-03-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.30 %
- 52 Week High 10.31
- 52 Week Low 2.60
About
Design Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Carlsbad, California, dedicated to developing groundbreaking therapies for degenerative disorders linked to nucleotide repeat expansions, including Friedreich's ataxia. With a proprietary pipeline of small-molecule drug candidates, the company aims to target the genetic mechanisms underlying these conditions, striving to restore normal cellular function and enhance patient outcomes. Committed to advancing clinical development and addressing significant unmet medical needs, Design Therapeutics is poised to establish itself as a prominent player in the biopharmaceutical landscape, particularly within the realm of rare genetic diseases.
Analyst Target Price
$13.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-03-17 | 2024-11-11 | 2024-08-05 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-05-09 | 2023-03-14 |
| Reported EPS | -0.3 | -0.34 | -0.31 | -0.24 | -0.23 | -0.21 | -0.2 | -0.21 | -0.28 | -0.36 | -0.35 | -0.31 |
| Estimated EPS | -0.3367 | -0.2967 | -0.28 | -0.2667 | -0.24 | -0.23 | -0.26 | -0.31 | -0.41 | -0.4 | -0.36 | -0.34 |
| Surprise | 0.0367 | -0.0433 | -0.03 | 0.0267 | 0.01 | 0.02 | 0.06 | 0.1 | 0.13 | 0.04 | 0.01 | 0.03 |
| Surprise Percentage | 10.8999% | -14.5939% | -10.7143% | 10.0112% | 4.1667% | 8.6957% | 23.0769% | 32.2581% | 31.7073% | 10% | 2.7778% | 8.8235% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3433 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DSGN
2026-01-01 02:09:42
Design Therapeutics (NASDAQ:DSGN) shares fell 4.5% during mid-day trading with increased volume, closing at $9.35. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $14.00, despite some recent "sell" downgrades. Fundamentals show a market cap of $536.85 million and a negative PE ratio, though Q3 earnings beat estimates.
2025-12-30 01:12:39
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a consensus "Moderate Buy" rating from five brokerage firms, with an average one-year price target of $14.00. Recent analyst activities include upgrades and new coverage, reflecting a generally positive outlook. The biopharmaceutical company, which uses its GeneTAC platform for genetic disease treatments, reported better-than-expected Q3 EPS and has significant institutional investment.
2025-12-20 08:09:13
Design Therapeutics' shares rallied by 7.88% to $9.72 following positive clinical and operational developments. The company reported $206.0 million in cash, cash equivalents, and marketable securities as of Q3 2025, and secured regulatory approval to begin clinical development for DT‑818 in Australia. Investors are focused on upcoming clinical milestones, including the initiation of patient dosing in H1 2026 and data readout in 2027, as key drivers for future performance.
2025-12-20 03:10:20
The provided content is empty, so a summary cannot be generated.
2025-12-19 04:09:59
Design Therapeutics (NASDAQ:DSGN) experienced a significant surge in trading volume, with approximately 618,642 shares traded, a 237% increase from the prior session. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $14. Institutional investors hold about 56.6% of the stock, and the company recently beat its quarterly EPS estimates.
2025-12-17 17:08:49
Shares of Design Therapeutics (NASDAQ:DSGN) dropped 4.5% during mid-day trading on Wednesday, closing at $9.19 with a significantly lower trading volume than average. Despite the stock's downturn, analyst sentiment remains mixed but leans positive, with several firms upgrading their ratings and setting an average price target of $14. The company, which has a market cap of $531 million, reported a quarterly EPS beat and institutional investors currently own over 56% of its stock.
